Bayer Cash on Hand 2012-2025 | BAYRY
Bayer cash on hand from 2012 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Bayer cash on hand for the quarter ending December 31, 2025 was $9.121B, a 0.33% decline year-over-year.
- Bayer cash on hand for 2025 was $9.121B, a 0.33% decline from 2024.
- Bayer cash on hand for 2024 was $9.151B, a 21.29% decline from 2023.
- Bayer cash on hand for 2023 was $11.627B, a 6.33% increase from 2022.
|
Bayer Annual Cash on Hand (Millions of US $) |
|
|---|---|
| 2025 | $9,121 |
| 2024 | $9,151 |
| 2023 | $11,627 |
| 2022 | $10,935 |
| 2021 | $9,354 |
| 2020 | $13,857 |
| 2019 | $6,172 |
| 2018 | $6,162 |
| 2017 | $12,558 |
| 2016 | $9,045 |
| 2015 | $2,904 |
| 2014 | $3,424 |
| 2013 | $3,242 |
| 2012 | $3,281 |
| 2011 | $2,465 |
|
Bayer Quarterly Cash on Hand (Millions of US $) |
|
|---|---|
| 2025-12-31 | $9,121 |
| 2025-09-30 | $8,465 |
| 2025-06-30 | $6,238 |
| 2025-03-31 | $5,672 |
| 2024-12-31 | $9,151 |
| 2024-09-30 | $6,970 |
| 2024-06-30 | $10,795 |
| 2024-03-31 | $9,687 |
| 2023-12-31 | $11,627 |
| 2023-09-30 | $10,129 |
| 2023-06-30 | $8,320 |
| 2023-03-31 | $8,560 |
| 2022-12-31 | $10,935 |
| 2022-09-30 | $9,139 |
| 2022-06-30 | $8,720 |
| 2022-03-31 | $9,195 |
| 2021-12-31 | $9,354 |
| 2021-09-30 | $9,692 |
| 2021-06-30 | $7,829 |
| 2021-03-31 | $11,227 |
| 2020-12-31 | $13,857 |
| 2020-09-30 | $18,166 |
| 2020-06-30 | $6,285 |
| 2020-03-31 | $5,572 |
| 2019-12-31 | $6,172 |
| 2019-09-30 | $6,176 |
| 2019-06-30 | $4,734 |
| 2019-03-31 | $5,581 |
| 2018-12-31 | $6,162 |
| 2018-09-30 | $7,498 |
| 2018-06-30 | $7,796 |
| 2018-03-31 | $15,546 |
| 2017-12-31 | $12,558 |
| 2017-09-30 | $3,992 |
| 2017-06-30 | $11,006 |
| 2017-03-31 | $4,372 |
| 2016-12-31 | $9,045 |
| 2016-09-30 | $3,791 |
| 2016-06-30 | $2,223 |
| 2016-03-31 | $4,525 |
| 2015-12-31 | $2,904 |
| 2015-09-30 | $4,380 |
| 2015-06-30 | $4,494 |
| 2015-03-31 | $2,771 |
| 2014-12-31 | $3,424 |
| 2014-09-30 | $8,225 |
| 2014-06-30 | $2,531 |
| 2014-03-31 | $4,688 |
| 2013-12-31 | $3,242 |
| 2013-09-30 | $3,121 |
| 2013-06-30 | $3,228 |
| 2013-03-31 | $2,784 |
| 2012-12-31 | $3,281 |
| 2012-09-30 | $3,744 |
| 2012-06-30 | $2,555 |
| 2012-03-31 | $6,160 |
| 2011-12-31 | $2,465 |
| 2011-09-30 | $1,672 |
| 2011-06-30 | $2,586 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $46.178B | $51.552B |
| Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |